Catalent, Inc. CTLT
63.48 0.00 (+0.00%)
At closeDec 17, 2024, 4:00 PM EST
63.44 Day range 63.50
52-week range unavailable
News
businesswire.com Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and…
reuters.com Scholar Rock drops Catalent facility from marketing application for muscle weakness drug Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.
globenewswire.com Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.
businesswire.com Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent's network.
businesswire.com Cartherics and Catalent Expand Commercial License Agreement MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian…
businesswire.com Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.
businesswire.com SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.
globenewswire.com Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies…
businesswire.com Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™” TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that…
proactiveinvestors.com Lisata Therapeutics CEO discusses Catalent deal - ICYMI Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability…- proactiveinvestors.com Lisata Therapeutics CEO discusses Catalent deal - ICYMI Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces its...
proactiveinvestors.com Lisata Therapeutics inks global product license deal with Catalent Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into…
benzinga.com Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy…
investors.com Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.
globenewswire.com Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.
globenewswire.com Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India,…
businesswire.com Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.
proactiveinvestors.com Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors…
proactiveinvestors.com Lisata Therapeutics signs research license with Catalent Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's…
globenewswire.com Lisata Therapeutics Announces Research License with Catalent BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies…
benzinga.com Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.
benzinga.com Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
benzinga.com Earnings Scheduled For February 9, 2024 Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.
benzinga.com Stocks Inch Higher On Soft PPI, 'Magnificent 7' Retest 2021 Record Highs: What's Driving Markets Wednesday? U.S. stocks trended higher on Wednesday, extending gains in a week marked by two soft inflation reports.
benzinga.com Earnings Scheduled For November 15, 2023 Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third…
benzinga.com Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for…
benzinga.com Earnings Scheduled For August 29, 2023 Companies Reporting Before The Bell • VEON (NASDAQ:VEON) is estimated to report earnings for its second quarter.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 120 stocks hit new 52-week lows.- benzinga.com Earnings Scheduled For May 15, 2023 Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 199 companies reached new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 164 companies hit new 52-week lows.
benzinga.com Earnings Scheduled For May 9, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 61 companies hit new 52-week lows.
- benzinga.com Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
- benzinga.com Crude Oil Rises Over 2%; US Wholesale Inventories Unchanged For March U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite dropping around 20 points on Monday. The Dow traded down 0.14% to 33,626.85 while the NASDAQ fell 0.18% to…
- benzinga.com US Stocks Edge Lower; Tyson Foods Posts Q2 Loss U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday. Following the market opening Monday, the Dow traded down 0.12% to 33,635.06 while the NASDAQ…
- benzinga.com Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
- benzinga.com Earnings Scheduled For February 7, 2023 Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
- benzinga.com Nasdaq Down Over 100 Points; Tyson Foods Posts Downbeat Earnings U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 80 points on Monday. The Dow traded down 0.15% to 33,875.74 while the NASDAQ fell 0.88% to 11,900.97. The…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 236 companies set new 52-week lows.
- benzinga.com Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 85 stocks hit new 52-week lows.
- benzinga.com Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
- benzinga.com Earnings Scheduled For November 1, 2022 Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 96 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday, 125 stocks hit new 52-week lows.